Assessing Reproductive Choices of Women and the Likelihood of Oocyte Cryopreservation in the Era of Elective Oocyte Freezing
Overview
Affiliations
Objective: To assess reproductive choices of reproductive-age women in the United States and factors that influence consideration of elective egg freezing (EF).
Design: Cross-sectional internet-based survey.
Setting: Not applicable.
Patients: One thousand women aged 21-45 years.
Intervention(s): An anonymous 63-item self-administered questionnaire was distributed to a representative cross-section of women aged 21-45 years, stratified by age <35 years. One-half of the sample had at least one child, and the other one-half did not. All of the participants were interested in having children.
Main Outcome Measure(s): Ordinal logistic regression was performed to characterize the association of population characteristics and reproductive knowledge with likelihood to consider EF. Willingness to pay was assessed with the use of a linear prediction model that calculated dollar amounts at varying success rates.
Result(s): Overall, 87.2% of the sample reported awareness of EF for fertility preservation and 25% would consider this option, yet only 29.8% knew what the EF process entails. Once informed of the process, 30% of women changed their level of consideration. In a multivariable model, Asian race, single status, and infertility increased the likelihood of considering EF. Women likely to consider egg freezing would be willing to pay $3,811.55 (95% confidence interval $2,862.66-$4,760.44). If the total cost were $10,000, 91% of the cohort would accept at minimum a 50% chance of successful delivery.
Conclusion(s): This study is one of the largest cohorts of reproductive-age women in the United States addressing reproductive choices and factors associated with the importance of having a biologically related child and the likelihood of considering EF to preserve fertility. This study provides important insight into the willingness to pay for this elective endeavor.
Clinical utilization and outcomes over eight consecutive years following oocyte cryopreservation.
Murugappan G, Sikder M, Vaccari S, Minjarez D, Tran N, Kim J J Assist Reprod Genet. 2024; 42(2):413-421.
PMID: 39633145 PMC: 11871152. DOI: 10.1007/s10815-024-03334-z.
Osaah M, Damalie F, Amoah V, Senaya C, Dankluvi H, Yeboah B BMC Womens Health. 2024; 24(1):553.
PMID: 39379906 PMC: 11459717. DOI: 10.1186/s12905-024-03387-3.
Patient experience of social and medical fertility preservation fully reimbursed in France.
Hagege E, Pirtea P, Burette J, Canepa A, Graesslin O, de Ziegler D J Assist Reprod Genet. 2024; 41(10):2813-2822.
PMID: 39138766 PMC: 11534921. DOI: 10.1007/s10815-024-03222-6.
Mashayekh-Amiri S, Jafarabadi M, Molaie B, Rashidi F, Hemati E, Aliasghari F Reprod Health. 2024; 21(1):57.
PMID: 38649965 PMC: 11572397. DOI: 10.1186/s12978-024-01795-0.
Yuan Y, Yang L, Hu J, Deng Y, Zhang H BMJ Open. 2024; 14(3):e080890.
PMID: 38431304 PMC: 10910424. DOI: 10.1136/bmjopen-2023-080890.